clinical trial · NCT07622186
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·phase2·recruiting·n = 150
Non-Small Cell Lung CancerSKB571 for injectionOsimertinibFurmonertinibcarboplatinCisplatinPembrolizumab
brief summary
This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB571 Combination Therapy in participants with Non-Small Cell Lung Cancer (NSCLC).
started
Jul 15, 2026
primary completion
Dec 31, 2028
completion
Dec 31, 2029
last updated
Sep 2, 2026
detailed description
This is a multicenter, open-label, Phase II clinical study to evaluate the efficacy, safety, tolerability, PK characteristics, and immunogenicity of SKB571Combination Therapy in participants with Non-Small Cell Lung Cancer (NSCLC). Approximately 150 subjects will be enrolled in this study, including 3 cohorts.
official title
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol